Cargando…
Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study
PURPOSE: To study post-interventional findings in patients with dysthyroid optic neuropathy (DON) treated with teprotumumab. OBSERVATIONS: In this multicenter observational Case series, patients with DON were treated with teprotumumab, an insulin-like growth factor I receptor inhibitor (10 mg/kg for...
Autores principales: | Sears, Connie M., Wang, Yao, Bailey, Lucy A., Turbin, Roger, Subramanian, Prem S., Douglas, Raymond, Cockerham, Kimberly, Kossler, Andrea L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170359/ https://www.ncbi.nlm.nih.gov/pubmed/34113737 http://dx.doi.org/10.1016/j.ajoc.2021.101111 |
Ejemplares similares
-
Hearing Loss and Teprotumumab
por: Kossler, Andrea, et al.
Publicado: (2021) -
Teprotumumab for the treatment of chronic thyroid eye disease
por: Ugradar, Shoaib, et al.
Publicado: (2021) -
Commentary: Dysthyroid optic neuropathy
por: Rath, Suryasnata
Publicado: (2022) -
Thyroid dermopathy responds to teprotumumab therapy
por: Crespo-Trevino, Ricaurte, et al.
Publicado: (2022) -
Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease
por: Kossler, Andrea Lora, et al.
Publicado: (2022)